BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35165762)

  • 21. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.
    Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC
    PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.
    Lan J; Huang HY; Lee SW; Chen TJ; Tai HC; Hsu HP; Chang KY; Li CF
    Tumour Biol; 2014 Jan; 35(1):179-87. PubMed ID: 23897556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
    Erriquez J; Becco P; Olivero M; Ponzone R; Maggiorotto F; Ferrero A; Scalzo MS; Canuto EM; Sapino A; Verdun di Cantogno L; Bruna P; Aglietta M; Di Renzo MF; Valabrega G
    Gynecol Oncol; 2015 Sep; 138(3):627-33. PubMed ID: 26100858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.
    Jain M; Zhang L; He M; Zhang YQ; Shen M; Kebebew E
    Endocr Relat Cancer; 2013 Jun; 20(3):361-70. PubMed ID: 23533247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting nucleolin for better survival in diffuse large B-cell lymphoma.
    Jain N; Zhu H; Khashab T; Ye Q; George B; Mathur R; Singh RK; Berkova Z; Wise JF; Braun FK; Wang X; Patel K; Xu-Monette ZY; Courty J; Young KH; Sehgal L; Samaniego F
    Leukemia; 2018 Mar; 32(3):663-674. PubMed ID: 28690315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topological regulation of the estrogen transcriptional response by ZATT-mediated inhibition of TOP2B activity.
    Terrón-Bautista J; Martínez-Sánchez MDM; López-Hernández L; Vadusevan AA; García-Domínguez M; Williams RS; Aguilera A; Millán-Zambrano G; Cortés-Ledesma F
    bioRxiv; 2024 Jan; ():. PubMed ID: 38328138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
    Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
    Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
    Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes.
    Varga Z; Moelans CB; Zuerrer-Hardi U; Ramach C; Behnke S; Kristiansen G; Moch H
    Breast Cancer Res Treat; 2012 Jun; 133(3):929-35. PubMed ID: 22083232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
    Pierceall WE; Sprott KM; Heikkinen T; Heikkila P; Alaparthi L; Aittomaki K; Al-Adhami M; Villegas-Bergazzi V; Meyer JL; Kutok JL; Bartkova J; Bartek J; Nevanlinna H; Weaver DT; Blomqvist C
    Hum Pathol; 2012 Sep; 43(9):1363-75. PubMed ID: 22204715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genome-wide TOP2A DNA cleavage is biased toward translocated and highly transcribed loci.
    Yu X; Davenport JW; Urtishak KA; Carillo ML; Gosai SJ; Kolaris CP; Byl JAW; Rappaport EF; Osheroff N; Gregory BD; Felix CA
    Genome Res; 2017 Jul; 27(7):1238-1249. PubMed ID: 28385713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TOPBP1 recruits TOP2A to ultra-fine anaphase bridges to aid in their resolution.
    Broderick R; Nieminuszczy J; Blackford AN; Winczura A; Niedzwiedz W
    Nat Commun; 2015 Mar; 6():6572. PubMed ID: 25762097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance.
    Wong N; Yeo W; Wong WL; Wong NL; Chan KY; Mo FK; Koh J; Chan SL; Chan AT; Lai PB; Ching AK; Tong JH; Ng HK; Johnson PJ; To KF
    Int J Cancer; 2009 Feb; 124(3):644-52. PubMed ID: 19003983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
    Konecny GE; Pauletti G; Untch M; Wang HJ; Möbus V; Kuhn W; Thomssen C; Harbeck N; Wang L; Apple S; Jänicke F; Slamon DJ
    Breast Cancer Res Treat; 2010 Apr; 120(2):481-9. PubMed ID: 20130985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.
    Liang Z; Zeng X; Gao J; Wu S; Wang P; Shi X; Zhang J; Liu T
    BMC Cancer; 2008 Dec; 8():363. PubMed ID: 19061514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
    Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
    Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NUP98 is fused to topoisomerase (DNA) IIbeta 180 kDa (TOP2B) in a patient with acute myeloid leukemia with a new t(3;11)(p24;p15).
    Nebral K; Schmidt HH; Haas OA; Strehl S
    Clin Cancer Res; 2005 Sep; 11(18):6489-94. PubMed ID: 16166424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
    Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.
    Romero A; Martín M; Cheang MC; López García-Asenjo JA; Oliva B; He X; de la Hoya M; García Sáenz JÁ; Arroyo Fernández M; Díaz Rubio E; Perou CM; Caldés Llopis T
    Am J Pathol; 2011 Apr; 178(4):1453-60. PubMed ID: 21435434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
    Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
    BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.